EUVIMEDObjevte EUVIMED
Übersichtsarbeit

Therapeutic implications of crocin in Parkinson's disease: A review of preclinical research

Ahsas Goyal iD, Aanchal Verma iD, Anant Agrawal iD, Nandini Dubey iD, Abhay Kumar iD, Tapan Behl iD

Chemical Biology & Drug Design · 2023

DOI: 10.1111/cbdd.14210 ↗

At a glance

Übersichtsarbeit in Chemical Biology & Drug Design, 2023. Written by Ahsas Goyal and 5 co-authors. Institution: Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India. Major MEDLINE topics: Parkinson Disease, Neuroprotective Agents. Cited 19 times so far (Crossref); 106 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Parkinson's disease is among the most common forms of neurodegenerative illness, with present treatment being primarily symptomatic and frequently coming with substantial adverse effects. Neuronal degeneration may arise due to a variety of pathological events, like inflammatory responses, neurotransmitter dysregulation, oxidative damage, mitochondrial malfunction, apoptosis, and genetic factors. The health issue and financial burden brought on by Parkinson's disease can worsen as the population ages. In the search for new and secure therapeutic agents for Parkinson's disease, several natural compounds have been shown to exert considerable neuroprotective benefits. Crocin, a naturally occurring carotenoid molecule, was found to have neuroprotective potential in the therapy of this disorder. Taking into account, the outcomes of various studies and the restorative actions of crocin, the present study emphasized the protective ability of crocin in this disease. Given the strong evidence supporting the neuroprotective ability of crocin, it is inferred that crocin inhibits inflammatory, apoptotic, and antioxidant processes through multiple mechanisms. Therefore, this compound is considered a safe and effective therapeutic choice for neurodegenerative illnesses like Parkinson's disease. However, more research on its efficacy as a treatment of Parkinson's disease is needed, specifically examining its mechanisms and the results obtained in clinical trials.

Subjects

MeSH terms (MEDLINE)

Parkinson DiseaseNeuroprotective AgentsHumansCarotenoidsAntioxidantsOxidative Stress

Author keywords

Parkinson's diseaseapoptosiscrocinneurodegenerationneuroinflammationoxidative stress

Substances

crocinNeuroprotective AgentsCarotenoidsAntioxidants

Authors and institutions

  • Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.
  • School of Health Sciences and Technology, University of Petroleum and Energy Studies, Bidohli, Uttarakhand, India.

ORCID profiles: Ahsas Goyal, Aanchal Verma, Anant Agrawal, Nandini Dubey, Abhay Kumar, Tapan Behl

Cite

APA

Goyal, A., Verma, A., Agrawal, A., Dubey, N., Kumar, A., & Behl, T. (2023). Therapeutic implications of crocin in Parkinson's disease: A review of preclinical research. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14210

Vancouver

Goyal A, Verma A, Agrawal A, Dubey N, Kumar A, Behl T. Therapeutic implications of crocin in Parkinson's disease: A review of preclinical research. Chemical Biology & Drug Design. 2023. doi:10.1111/cbdd.14210

BibTeX
@article{Goyal2023,
  author = {Goyal, Ahsas and Verma, Aanchal and Agrawal, Anant and Dubey, Nandini and Kumar, Abhay and Behl, Tapan},
  title = {Therapeutic implications of crocin in Parkinson's disease: A review of preclinical research},
  journal = {Chemical Biology & Drug Design},
  year = {2023},
  doi = {10.1111/cbdd.14210}
}
Start for free →